BOURLA ALBERT received 22 derivative securities of PFIZER INC at $27.55 per share on 2026-09-15, bringing his reported holding to 783,985 derivative securities. The transaction was classified as an award under code A and represented about 0.0% of his resulting derivative securities position.
Key Highlights
- BOURLA ALBERT’s resulting PFIZER INC derivative securities holding was 783,985.
- The transaction represented about 0.0% of his resulting derivative securities holding.
- SEC transaction code A classified the transaction as an award or grant dated 15 September 2026.
BOURLA ALBERT received 22 derivative securities of PFIZER INC at $27.55 per share on 15 September 2026. The award increased his reported derivative securities position to 783,985. The transaction carried SEC code A, which denotes an award or grant.
Resulting Derivative Securities Position
The reported position after the transaction stood at 783,985 derivative securities of PFIZER INC. The 22-security award represented about 0.0% of BOURLA ALBERT’s resulting derivative securities holding. The percentage describes the transaction relative to the post-transaction position.
FAQs
Q: How many Pfizer derivative securities did Bourla Albert receive?
A: BOURLA ALBERT received 22 derivative securities of PFIZER INC. The securities were awarded at $27.55 per share on 15 September 2026.
Q: What was Bourla Albert’s Pfizer derivative securities holding afterward?
A: BOURLA ALBERT’s reported PFIZER INC derivative securities holding after the transaction was 783,985. The transaction represented about 0.0% of that resulting position.
Q: What does transaction code A mean in Bourla Albert’s Pfizer transaction?
A: SEC transaction code A identifies an award or grant. The transaction involved derivative securities of PFIZER INC and was dated 15 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.